MannKind (MNKD) Company Sales Revenue

MannKind - graphic logo of issuer MNKD

MannKind Corporation (MNKD) business growth relies on a strategic alliance with an industry behemoth and the sale of inhaled insulin. Stable demand for life-saving therapy guarantees resilience against any market volatility. The company's consolidated sales dynamics clearly demonstrate this trend, where the 0.41 level captures the current state. Michael Castagna is developing innovative drug delivery methods, optimizing the enterprise's operational efficiency.

Revenue and Sales Volume: MannKind Corp. (MNKD) for 07/04/2022 - 11/17/2026

Analytical breakdowns for MannKind Corporation

- market price and analyst price targets:
Comprehensive company analysis:MNKD, MannKind Corporation
Product sample of Afrezza

The scalability of inhalable insulin production at MannKind Corporation (MNKD) creates powerful operating leverage as shipments grow. This metric captures the speed at which market demand transforms into actual revenue, reflecting the efficiency of fixed cost allocation. The indicator measures the intensity of operating income during new product launches. Analysis of daily price action allows for the timely recognition of emotional overheating of the asset. The company's product sales trend serves as a tool to avoid purchasing shares at a valuation peak.

Key competitors

HLN: Company Sales Revenue|Company Revenue Kenvue (KVUE)|VRNA (Verona Pharma Corp) - Company Sales Revenue|Company Revenue Jyong Biotech MENS|Ligand Pharma - Company Revenue|AMRX - Company Revenue|Company Total Revenue perrigo.com|ALVO (Alvotech SA) - Company Sales|Company Total Sales Volume Liquidia Technologies LQDA|GLPG (Galapagos N.V.) - Revenue and Sales Volume|ANIP: Company Sales Revenue|Revenue and Sales Volume AMPH|PCRX (Pacira BioSciences) - Company Sales Revenue|Revenue and Sales Volume SPRY (ARS Pharmaceuticals, Inc.)|Theravance Biopharma, Inc. - Company Revenue|Aquestive Corp - Revenue and Sales Volume|scpharmaceuticals.com (SCPH) - Company Sales|TECX: Revenue and Sales Volume|Tonix Pharmaceuticals - Company Sales Revenue|Company Sales SXTC|EPRX: Company Sales Revenue|Company Sales BHST (BioHarvest Sciences Inc.)|Company Gross Revenue Invizyne|Company Revenue Oramed Pharmaceuticals ORMP|Company Sales Revenue ENTX|HYFT - Company Revenue|Company Sales Revenue ABVC (ABVC BioPharma Inc.)|CPIX: Revenue and Sales Volume|Quantum BioPharma Limited - Company Sales Revenue|FGEN (FibroGen Corp) - Revenue and Sales Volume|Revenue and Sales Volume Telomir Pharmaceuticals|Revenue and Sales Volume RANI|SNYR (Synergy CHC Corp.) - Company Sales Revenue|Revenue and Sales Volume RLYB (Rallybio Corp)|LEXX: Company Sales Volume|PULM - Company Revenue|PTHL: Company Revenue|APM (aptorumgroup.com) - Company Sales|Lyra Therapeutics - Company Sales Revenue|Company Revenue Impact BioMedical Inc|TNF Pharmaceuticals, Inc. (TNFA) - Company Gross Revenue|Revenue and Sales Volume YCBD|PRFX: Company Annual Revenue|Company Revenue altamiratherapeutics.com CYTO|Revenue and Sales Volume Lipella Pharmaceuticals Inc LIPO|OPTN - Company Revenue|Company Gross Revenue Pieris Pharma PIRS|Procaps Group SA (PROC) - Company Revenue|Company Annual Revenue PTPI (Petros Pharmaceuticals, Inc.)|QLI (Qilian International Holding) - Revenue and Sales Volume|SLRN: Company Sales Revenue|Revenue and Sales Volume TFFP